• 6154 Citations
  • 39 h-Index
If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where ByoungChul Cho is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 15 Similar Profiles
Non-Small Cell Lung Carcinoma Medicine & Life Sciences
Epidermal Growth Factor Receptor Medicine & Life Sciences
Mutation Medicine & Life Sciences
Protein-Tyrosine Kinases Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Disease-Free Survival Medicine & Life Sciences
Drug Therapy Medicine & Life Sciences
Survival Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2004 2019

3 Citations (Scopus)

A phase I/IB trial of the vegfr-sparing multikinase ret inhibitor RXDX-105

Drilon, A., Fu, S., Patel, M. R., Fakih, M., Wang, D., Olszanski, A. J., Morgensztern, D., Liu, S. V., Cho, B., Bazhenova, L., Rodriguez, C. P., Doebele, R. C., Wozniak, A., Reckamp, K. L., Seery, T., Nikolinakos, P., Hu, Z., Oliver, J. W., Trone, D., McArthur, K. & 3 others, Patel, R., Multani, P. S. & Ahn, M. J., 2019 Mar 1, In : Cancer Discovery. 9, 3, p. 384-395 12 p.

Research output: Contribution to journalArticle

Open Access
Non-Small Cell Lung Carcinoma
Gene Fusion

A phase Ib study of the combination of afatinib and ruxolitinib in EGFR mutant NSCLC with progression on EGFR-TKIs

Park, J. S., Hong, M. H., Chun, Y. J., Kim, H. R. & Cho, B., 2019 Aug 1, In : Lung Cancer. 134, p. 46-51 6 p.

Research output: Contribution to journalArticle

Epidermal Growth Factor Receptor
Protein-Tyrosine Kinases
Disease Progression

Characterization of head and neck squamous cell carcinoma arising in young patients: Particular focus on molecular alteration and tumor immunity

Ryu, H. J., Kim, E. K., Cho, B. & Yoon, S., 2019 Jan 1, In : Head and Neck. 41, 1, p. 198-207 10 p.

Research output: Contribution to journalArticle

Tumor-Infiltrating Lymphocytes
Fluorescence In Situ Hybridization

Comprehensive analysis of the characteristics and treatment outcomes of patients with non-small cell lung cancer treated with anti-PD-1 therapy in real-world practice

Ahn, B. C., Pyo, K. H., Xin, C. F., Jung, D., Shim, H. S., Lee, C. Y., Park, S. Y., Yoon, H. I., Hong, M. H., Cho, B. & Kim, H. R., 2019 Jan 1, In : Journal of cancer research and clinical oncology.

Research output: Contribution to journalArticle

Open Access
Non-Small Cell Lung Carcinoma
Disease-Free Survival
Confidence Intervals
1 Citation (Scopus)

Efficacy and Safety of Ceritinib (450 mg/d or 600 mg/d) With Food Versus 750-mg/d Fasted in Patients With ALK Receptor Tyrosine Kinase (ALK)–Positive NSCLC: Primary Efficacy Results From the ASCEND-8 Study

Cho, B., Obermannova, R., Bearz, A., McKeage, M., Kim, D. W., Batra, U., Borra, G., Orlov, S., Kim, S. W., Geater, S. L., Postmus, P. E., Laurie, S. A., Park, K., Yang, C. T., Ardizzoni, A., Bettini, A. C., de Castro, G., Kiertsman, F., Chen, Z., Lau, Y. Y. & 3 others, Viraswami-Appanna, K., Passos, V. Q. & Dziadziuszko, R., 2019 Jan 1, In : Journal of Thoracic Oncology.

Research output: Contribution to journalArticle

Open Access
Confidence Intervals
Advisory Committees

Press / Media

Repotrectinib highly active in ROS1-positive lung cancer

ByoungChul Cho


3 items of media coverage

Press/Media: Press / Media